Search
Ibalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalIn October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] … It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseCrovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Tetracaine
go.drugbank.com/drugs/DB09085ApprovedInvestigationalVet approvedTetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Mixtures: Test Thin-Layer Rapid Use Patch TestCategories: Anesthetics for Topical Use, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigational[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved … Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigationalVamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainAlbuterol
go.drugbank.com/drugs/DB01001ApprovedInvestigationalVet approvedSalbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. … However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug.
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalIts use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.[L44758] … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.
Zidebactam
go.drugbank.com/drugs/DB13090Approved[L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.
Categories: Antiinfectives for Systemic UseDopamine
go.drugbank.com/drugs/DB00988ApprovedInvestigationalOne of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regu...
Mixtures: Dopamine HCl 3.2mg/ml Dextrose 5% Inj USP, Dopamine HCl 1.6mg/ml Dextrose 5% Inj USP